Quick Answer
NovoCure Ltd reported Operating Income of -$153.80 million for fiscal year 2025.
NovoCure Ltd Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$153.80M | +9.8% |
| 2024 | -$170.50M | +26.8% |
| 2023 | -$232.87M | -160.1% |
| 2022 | -$89.52M | -101.9% |
| 2021 | -$44.33M | -245.8% |
| 2020 | $30.40M | +3426.1% |
| 2019 | -$914.0K | +97.3% |
| 2018 | -$33.67M | +14.4% |
| 2017 | -$39.33M | +65.9% |
| 2016 | -$115.32M | -10.9% |
| 2015 | -$104.00M | -29.7% |
| 2014 | -$80.16M | -24.4% |
| 2013 | -$64.46M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.02M | -12.2% | +8.9% |
| June 30, 2025 | -$39.52M | -17.7% | -4.4% |
| March 31, 2025 | -$37.87M | +8.8% | -18.0% |
| September 30, 2024 | -$32.09M | +44.9% | +4.4% |
| June 30, 2024 | -$33.58M | +46.4% | +19.1% |
| March 31, 2024 | -$41.52M | +31.1% | +28.7% |
| September 30, 2023 | -$58.24M | -136.7% | +7.0% |
| June 30, 2023 | -$62.66M | -196.6% | -4.0% |
- NovoCure Ltd showed an increase of +9.8% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, NovoCure Ltd’s operating income has declined by 138.6% (from -$64.46 million to -$153.80 million).
- The most recent figure is from NovoCure Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: